![Han Jing Xie](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Han Jing Xie
Directeur Technique/Scientifique/R&D chez
Idogen AB
Profil
Han Jing Xie is an Associate Professor at Karolinska Institutet and the Chief Medical Officer at Idogen AB. Prior to these roles, Xie was a Senior Director-Medical Study at Oncopeptides AB and the Head-Cancer Clinical Trial Unit at Capio St Gorans Hospital.
Xie earned a doctorate degree from Karolinska Institutet in 2004.
Postes actifs de Han Jing Xie
| Sociétés | Poste | Début |
|---|---|---|
Idogen AB
 Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Directeur Technique/Scientifique/R&D | 01/01/2022 |
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Han Jing Xie
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOPEPTIDES AB | Corporate Officer/Principal | 01/01/2022 |
Capio St Gorans Hospital | Corporate Officer/Principal | 01/01/2020 |
Formation de Han Jing Xie
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
86
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Idogen AB
Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Health Technology |
Capio St Gorans Hospital |
